An interventional study of conventional physical therapy and Extracorporeal shock wave therapy in Plantar Fasciitis, Chronic, sponsored by Ibrahim Abuomar Fadulaalhq Alramadhani. Active, not recruiting at 1 site in Saudi Arabia. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-06-26.
Sponsored by Ibrahim Abuomar Fadulaalhq Alramadhani · Not applicable, Interventional, and Treatment
Plantar fasciitis is a common painful condition. It accounts for 10-15% of all foot painful conditions. Recently, Extracorporeal shock wave therapy (ESWT) was used as an effective method in treatment of different musculoskeletal disorders. High-intensity laser therapy (HILT) is a relatively recent treatment option that has shown benefits in a wide range of musculoskeletal disorders.
267 studies on the registry are indexed under Fasciitis, Plantar; 70 are open to participants now.
This study's planned enrollment of 60 is close to the median of 56 across 233 interventional studies indexed under Fasciitis, Plantar.
Browse Fasciitis, Plantar studies →This is the only study on the registry with Ibrahim Abuomar Fadulaalhq Alramadhani as lead sponsor.
Counted across the registry records on this site, refreshed daily.
1. Patients will be included according to the diagnostic criteria for plantar fasciitis of the American physical therapy association (APTA) (Martin et al., 2014). This criterion includes pain in medial sole and heel of foot: most pronounced in initial steps after a period of inactivity, it also worsens after prolonged weight bearing, pain during palpation and compression of proximal plantar fascia, limited range of motion in active and passive ankle dorsiflexion, positive windlass test.
2. Patients will be referred from an orthopedic surgeon with confirmed diagnosis of plantar fasciitis (Bidoki et al., 2024).
3. Patients with chronic plantar fasciitis (Duration of patient's symptoms will be more than three months) (Riaz et al., 2023).
4. Patients' age will range from 18 to 45 years (Bidoki et al., 2024). 5. Both genders (Riaz et al., 2023). 6. Localized non radiating foot pain with an NPRS more than 5 on the first step in the morning (Riaz et al., 2023).
Exclusion Criteria:
Patients will be excluded if they present any of the following criteria
Group (A)
Other: conventional physical therapy
Group (B)
Other: Extracorporeal shock wave therapy
Group (C)
Other: High-intensity laser therapy
exercise
ESWT
HILT
Hand held dynamometer
Hand held dynamometer is a portable device, characterized as a low-cost and convenience to assess muscle strength in a clinical setting
Time frame: 6 weeks
Ultrasonography
Ultrasonography is a type of medical imaging device that uses high-frequency sound (ultrasound) waves to produce images of internal organs and other tissues such as tendons, muscles, joints, blood vessels, and internal organs, to measure some characteristics
Time frame: 6 weeks
Arabic version of foot function index (FFI-Ar)
Foot functional index is a self-administered index consisting of 23 items divided into 3 subcategories on the basis of: pain, disability and activity limitation.
Time frame: 6 weeks
Arabic version of numerical pain rating scale (NPRS-Ar)
The Numerical Rating Scale is an 11-point (0-10) Scale that measures pain intensity, it is considered a very sensitive pain assessment scale.
Time frame: 6 weeks
Documents are hosted by the registry — open the source record to download them.
Plan to share: No — Because it is top secrets for them and they refused.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.